Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Time for your weekly edition of the Defector Funbag. Got something on your mind? Email the Funbag. You can also read Drew over at SFGATE, and buy Drew’s books while you’re at it. Today, we’re talking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback